Boston Scientific CorporationNYSE: BSX

Learn about our Q3 2026 earnings

· Issued by Boston Scientific Corporation

Summary by 6ix AI

Boston Scientific reported net sales of $5.138 billion for the third quarter of 2026, up 1.5% on both a reported and an organic (company-adjusted) basis compared with the same period a year earlier.

Key details

  • Boston Scientific says net sales grew in each of its reportable business segments in the third quarter of 2026.
  • Its MedSurg segment grew 0.7% on an organic basis and its Cardiovascular segment grew 1.9% on an organic basis, both compared with the prior year period.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/boston-scientific-learn-about-our-q3-2026-earnings

Watch Boston Scientific's latest callBoston Scientific (NYSE:BSX) Q3 2026 Earnings Call · Replay · Oct 28Read the transcript of Boston Scientific (NYSE:BSX) Q3 2026 Earnings Call
Today, Boston Scientific shared its financial results for the third quarter of 2026. Overall, we generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5% on a reported and organic basis1 compared to the prior year period. We also achieved net sales growth in each of our reportable segments, with 0.7% organic growth1 in MedSurg and 1.9% organic growth1 in Cardiovascular compared to the prior year period. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Boston Scientific Corporation on 6ix

In the deck

Story so far

Earlier from Boston Scientific

All Boston Scientific news releases